Squarepoint Ops LLC decreased its holdings in shares of Liquidia Corporation (NASDAQ:LQDA – Free Report) by 81.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,422 shares of the company’s stock after selling 132,267 shares during the quarter. Squarepoint Ops LLC’s holdings in Liquidia were worth $2,346,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LQDA. California State Teachers Retirement System raised its holdings in Liquidia by 8,055.4% during the second quarter. California State Teachers Retirement System now owns 5,907,594 shares of the company’s stock worth $471,012,000 after purchasing an additional 5,835,156 shares in the last quarter. Bank of America Corp DE boosted its stake in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Liquidia during the second quarter worth about $29,694,000. Eversept Partners LP increased its position in shares of Liquidia by 33.0% during the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock worth $25,565,000 after purchasing an additional 167,949 shares in the last quarter. Finally, Seven Fleet Capital Management LP increased its position in shares of Liquidia by 25.2% during the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock worth $20,459,000 after purchasing an additional 51,727 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Liquidia
In other Liquidia news, insider Jason Adair sold 73,631 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $69.09, for a total value of $5,087,165.79. Following the completion of the transaction, the insider directly owned 174,606 shares of the company’s stock, valued at approximately $12,063,528.54. This trade represents a 29.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Rielly-Gauvin sold 18,393 shares of Liquidia stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $72.23, for a total transaction of $1,328,526.39. Following the sale, the director owned 44,637 shares of the company’s stock, valued at approximately $3,224,130.51. The trade was a 29.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 705,027 shares of company stock valued at $54,473,044. 25.60% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Liquidia
Liquidia Trading Down 2.1%
Shares of LQDA stock opened at $65.31 on Tuesday. The business’s fifty day moving average price is $77.19 and its 200 day moving average price is $59.67. The firm has a market capitalization of $5.85 billion, a PE ratio of 47.67 and a beta of 0.53. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. Liquidia Corporation has a 1-year low of $21.15 and a 1-year high of $93.61.
Liquidia (NASDAQ:LQDA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. Liquidia’s revenue for the quarter was up 1842.1% on a year-over-year basis. As a group, sell-side analysts forecast that Liquidia Corporation will post 2.57 EPS for the current fiscal year.
Liquidia Profile
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.
Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.
Featured Articles
- Five stocks we like better than Liquidia
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Corporation (NASDAQ:LQDA – Free Report).
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.
